Linda Liu & Partners’ Biotech Team Attends the 11th IP Frontier Pharmaceutical Forum (IFPF 2026)
From September 16 to 18, 2026, the 11th IP Frontier Pharmaceutical Forum (IFPF 2026) was held in Shanghai. Under the theme “Innovation, Protection, and Globalization: A New Ecosystem for Pharmaceutical IP,” the forum brought together patent office officials, judges, industry experts, and corporate IP leaders from China, the United States, Europe, and emerging markets to discuss cutting-edge issues in pharmaceutical IP reform and industry development. Linda Liu & Partners sent Mr. Tengfei Shi, Ms. Yu Bai, and Mr. Hao Zhang as representatives to attend and engage with global peers.
The forum featured systematic discussions on key topics including pharmaceutical patent term extension and test data protection, patent protection for second medical uses, IP strategies for drug conjugates, and IP portfolio planning for pharmaceutical companies going global.
During the forum, the firm’s representatives actively participated in discussions on core issues and exchanged views with experts from leading domestic and international institutions on practical matters such as pharmaceutical patent portfolio strategy, cross-border rights confirmation, and dispute resolution. They also held in-depth discussions with IP heads at multiple pharmaceutical companies and key players in biotech, sharing practical experience on building high-value IP systems and staying ahead in fierce global competition.
The event further clarified industry trends and the firm’s service direction, reinforcing its commitment to deepening its expertise in pharmaceutical IP. Looking ahead, Linda Liu & Partners will continue to closely follow policy changes and industry needs, using professional services to help Chinese pharmaceutical companies solidify the IP foundation for global development, safeguard innovation, and empower global expansion.
